The relationship between glycemic control and osteocalcin, type 1 collagen C-terminal telopeptide, bone-specific alkaline phosphatase and the effects of anti-diabetic regimens on circulating markers of bone turnover in newly diagnosed diabetic patients: B

2021 ◽  
Author(s):  
Burçak Karadeniz ◽  
Ceren Gur ◽  
Damla Cakir ◽  
Huseyin Cetin ◽  
Ozcan Sonmez ◽  
...  
Keyword(s):  
Alkaline Phosphatase ◽  
Glycemic Control ◽  
Diabetic Patients ◽  
Newly Diagnosed ◽  
Specific Alkaline Phosphatase ◽  
Bone Specific Alkaline Phosphatase ◽  
Markers Of Bone Turnover ◽  
Circulating Markers ◽  
The Relationship

scholarly journals Effects of telmisartan and losartan treatments on bone turnover markers in patients with newly diagnosed stage I hypertension

2019 ◽  
Vol 20 (3) ◽  
pp. 147032031986274 ◽  
Author(s):  
Berna İ Aydoğan ◽  
Emrah Erarslan ◽  
Uğur Ünlütürk ◽  
Sevim Güllü
Keyword(s):  
Vitamin D ◽  
Alkaline Phosphatase ◽  
Stage I ◽  
Peroxisome Proliferator ◽  
Newly Diagnosed ◽  
Peroxisome Proliferator Activated Receptor ◽  
Specific Alkaline Phosphatase ◽  
Bone Specific Alkaline Phosphatase ◽  
25 Hydroxy Vitamin D ◽  
Turnover Markers

Introduction: Telmisartan is an angiotensin-II receptor type-1 blocker and a partial agonist for peroxisome proliferator-activated receptor-γ. The aim of this study was to determine the potential effects of telmisartan on bone metabolism and turnover markers. Methods: Forty-two patients with newly diagnosed stage I hypertension who were prescribed telmisartan 80 mg/day or losartan 100 mg/day were included. Serum levels of calcium, phosphorus, 25-hydroxy vitamin D, bone-specific alkaline phosphatase, osteocalcin, interleukin 6 and 24-hour urinary N-terminal telopeptide were measured at the beginning and after 12 weeks of treatment. Results: When treatment arms were evaluated together, significantly increased 25-hydroxy vitamin D levels ( p=0.01), and decreased parathormone (PTH) ( p<0.001), bone-specific alkaline phosphatase ( p=0.01), osteocalcin ( p=0.045), urinary N-terminal telopeptide ( p<0.001) and interleukin 6 levels ( p=0.006) were observed. After eliminating the 25-hydroxy vitamin D effect, significant changes were not observed at any of the parameters. None of the levels of parameters were different between groups. Conclusions: Neither telmisartan, despite its partial peroxisome proliferator-activated receptor-γ agonistic effect, nor losartan treatment had significant effects on bone turnover markers in newly diagnosed stage I hypertensive patients.

Anxiety and Poor Glycemic Control: A Meta-Analytic Review of the Literature

2002 ◽  
Vol 32 (3) ◽  
pp. 235-247 ◽  
Author(s):  
Ryan J. Anderson ◽  
Allison B. Grigsby ◽  
Kenneth E. Freedland ◽  
Mary De Groot ◽  
Janet B. McGill ◽  
...  
Keyword(s):  
Glycemic Control ◽  
Meta Analysis ◽  
Poor Glycemic Control ◽  
Diabetic Patients ◽  
Collective Data ◽  
Diagnostic Interviews ◽  
Analytic Review ◽  
The Relationship

Objective: To determine whether anxiety is associated with poor glycemic control in adults with type 1 or type 2 diabetes. Method: MEDLINE, PubMed, and PsycINFO databases were used to locate studies that measured the association of anxiety with glycemic control. Meta-analytic procedures were used to convert the findings to a common metric, compute effect sizes (ES), and statistically analyze the collective data. Results: The search procedures identified 12 studies, 11 (92 percent) of which satisfied the criteria for inclusion in the meta-analysis. In this overall group, anxiety was not associated with glycemic control ( p = 0.19), although the ES was marginally statistically significant (ES = .09, 95 percent CI = 0.04 to 0.14). In studies that determined anxiety from diagnostic interviews, anxiety was associated with hyperglycemia ( p = 0.003) and the ES was also statistically significant (ES: 0.25, 95 percent CI = 0.10 to 0.38). Conclusions: The existing literature suggests that anxiety disorders are associated with hyperglycemia in diabetic patients. Additional studies are required to confirm the magnitude of the relationship, to elucidate moderating and causal factors, and to determine whether successful treatment of anxiety improves glycemic control.

scholarly journals Effects of Soy Isoflavones on Markers of Bone Turnover in Premenopausal and Postmenopausal Women*

2000 ◽  
Vol 85 (9) ◽  
pp. 3043-3048 ◽  
Author(s):  
Kerry E. Wangen ◽  
Alison M. Duncan ◽  
Barb E. Merz-Demlow ◽  
Xia Xu ◽  
Robert Marcus ◽  
...  
Keyword(s):  
Alkaline Phosphatase ◽  
Bone Turnover ◽  
Postmenopausal Women ◽  
Soy Isoflavones ◽  
Type I ◽  
Small Magnitude ◽  
Specific Alkaline Phosphatase ◽  
Bone Specific Alkaline Phosphatase ◽  
Markers Of Bone Turnover ◽  
Cross Links

Abstract Soy isoflavones are hypothesized to exert hormonal effects in women and thus may play a role in bone metabolism throughout life. In 2 randomized, cross-over studies, 14 pre- and 17 postmenopausal women were given 3 soy protein isolates containing different amounts of isoflavones [control, 0.13; low isoflavone (low-iso), 1.00; and high-iso, 2.01 mg/kg body wt·day, averaging 8, 65, and 130 mg/day, respectively], for over 3 months each. Food records, blood samples, and 24-h urine collections were obtained throughout the studies. The endpoints evaluated included plasma or serum concentrations of bone-specific alkaline phosphatase, osteocalcin, insulin-like growth factor-I (IGFI), IGF binding protein-3 (IGFBP3), and urine concentrations of deoxypyridinoline cross-links and carboxy-terminal telopeptide of type I collagen. In premenopausal women, IGFI and IGFBP3 concentrations were increased by the low-iso diet, and deoxypyridinoline cross-links was increased by both the low- and high-iso diets during certain phases of the menstrual cycle. In postmenopausal women, bone-specific alkaline phosphatase was decreased by both the low- and high-iso diets, and there were trends toward decreased osteocalcin, IGFI, and IGFBP3 concentrations with increasing isoflavone consumption. Although soy isoflavones do affect markers of bone turnover, the changes observed were of small magnitude and not likely to be clinically relevant. These data do not support the hypothesis that dietary isoflavones per se exert beneficial effects on bone turnover in women.

Effect of the ERα agonist GTx-758 on bone turnover markers in men with advanced prostate cancer.

2013 ◽  
Vol 31 (6_suppl) ◽  
pp. 222-222
Author(s):  
Evan Y. Yu ◽  
Thomas E. Keane ◽  
Ronald Tutrone ◽  
Laurence Belkoff ◽  
Joel Bass ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Clinical Trial ◽  
Alkaline Phosphatase ◽  
Bone Turnover ◽  
Phase Ii ◽  
Advanced Prostate Cancer ◽  
Specific Alkaline Phosphatase ◽  
Bone Specific Alkaline Phosphatase ◽  
Markers Of Bone Turnover ◽  
Venous Thromboembolic Events

222 Background: Men with advanced prostate cancer are being treated with androgen deprivation therapy (ADT) for longer periods of time. The use of ADT can be limited by estrogen deficiency side effects, including a loss of bone and a higher incidence of fractures. GTx-758 is an ERα agonist that lowers serum free testosterone greater than an LHRH agonist. Herein we compare the effects of GTx-758 and leuprolide on markers of bone turnover, C-terminal telopeptides and bone specific alkaline phosphatase, in men with advanced prostate cancer treated with ADT. Methods: In a Phase II study (G200705), men with advanced prostate cancer (n=159) received 1000 mg or 2000 mg of GTx-758 daily or leuprolide. Serum samples were collected and analyzed by a reference laboratory. C-terminal telopeptides (pg/ml) and bone specific alkaline phosphatase (U/L) were measured as indicators of bone turnover. All p values describe the comparison of the GTx-758 treatment groups to the leuprolide treated men at day 120. Results: Men receiving the 1000 mg and 2000 mg doses of GTx-758 had lower C-terminal telopeptide levels with a mean percentage change of -56.9 ± 12.5 and -54.8 ± 23.1, respectively, as compared with an increase of 46.0 ± 48.9 percentage in the men receiving the leuprolide (p<0.001). Similarly, bone specific alkaline phosphatase levels were lower in men treated with GTx-758, with mean percentage changes of-28.5 ± 11.7 and -19.8 ± 14.7, respectively, compared with an increase of 8.1 ± 24.3 percent in the leuprolide treated group (p<0.001). As a result of an increased risk of venous thromboembolic events (VTEs) at these higher doses of GTx-758, the trial was stopped prior to its completion and not all of the men on the study reached the 120 day treatment dates (71 evaluable). Conclusions: Patients receiving GTx-758 experienced a significant decrease in markers of bone turnover indicating potential improvement and not a loss of bone on ADT. Since changes in bone mineral density are a major side effect that can negatively affect the quality of life in men on ADT, the improvements in bone turnover observed in men treated with GTx-758 could be significant. A Phase II clinical trial utilizing lower doses of GTx-758 (G200712) is currently being performed. Clinical trial information: NCT01326312.

scholarly journals Serum ErbB2 concentration positively correlated to the glycemic variations in newly diagnosed Type 2 diabetic patients

2020 ◽  
Author(s):  
Yan Huang ◽  
Xia Han ◽  
Feng-fei Li ◽  
Yan-mei Liu ◽  
Zelong Liu ◽  
...  
Keyword(s):  
Glycemic Control ◽  
Mean Amplitude ◽  
Diabetic Patients ◽  
Newly Diagnosed ◽  
Type 2 Diabetic Patients ◽  
Mean Glucose ◽  
The Relationship ◽  
Type 2 Diabetic ◽  
Glycemic Variations

Abstract Background Accumulated evidences indicate that elevated levels of circulating ErbB2 are closely associated with increased incidence of diabetes. However, the relationship between ErbB2 concentration and glycemic variations (GV) in type 2 diabetic (T2D) patients remains elucidated. The aim of this study was to assess whether there is an association between serum ErbB2 concentration and GV in newly diagnosed T2D patients. Methods This was a three-center, and observational study. Between April 2019 and July 2019, a total of 106 newly diagnosed T2D patients were recruited. All recruited subjects were admitted as inpatients and received anti-diabetes agents free during the study period. At baseline, fasting serum was collected for ErbB2 measurement and all recruited patients were subjected a prospective CGM for at least 3 days. The primary endpoint was the relationships between ErbB2 concentrations and GV in T2D patients. Results Data of a total of 95 subjects who met the inclusion criteria were analyzed at the endpoint. Subjects were divided into quartiles according to their serum ErbB2 concentrations. We observed that subjects with an elevated level of ErbB2 had a higher value of GV in terms of mean amplitude of glucose excursion (MAGE), standard deviation of mean glucose (SDMG), and the coefficient of variation (CV%) than those with lower levels (all P<0.05). Multiple linear regression analyzes after adjusting for confounder factors indicate that serum ErbB2 levels were significantly positively correlated with the MAGE (β=0.664, t=7.218, P<0.01), SD (β=0.469, t=5.125, P<0.01) and CV% (β=0.337, t=4.442, P<0.01), respectively. Conclusion Serum ErbB2 concentration was positively correlated to the glycemic variations in newly diagnosed T2D patients. Our data indicating that ErbB2 may be a potential treatment target for diabetic patients for improvement in glycemic control. Keywords Type 2 Diabetes, glycemic control, ErbB2

scholarly journals Opposite correlation of 25-hydroxy-vitamin D- and 1,25-dihydroxy-vitamin D-metabolites with gestational age, bone- and lipid-biomarkers in pregnant women

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Oleg Tsuprykov ◽  
Saban Elitok ◽  
Claudia Buse ◽  
Chang Chu ◽  
Bernhard Karl Krämer ◽  
...  
Keyword(s):  
Vitamin D ◽  
Alkaline Phosphatase ◽  
Pregnant Women ◽  
Clinical Chemistry ◽  
Water Soluble ◽  
Target Cells ◽  
Vitamin D Metabolites ◽  
Specific Alkaline Phosphatase ◽  
Bone Specific Alkaline Phosphatase ◽  
Group B

Abstract25-Hydroxyvitamin D (25OHD) and 1,25-dihydroxyvitamin D (1,25(OH)2D) need to be bound to carrier proteins to be transported to their target cells. The majority of either 25OHD or 1,25(OH)2D is bound to vitamin D-binding protein (DBP), a smaller fraction is bound to albumin and only very small amounts of 25OHD or 1,25(OH)2D are free. Albumin-bound 25OHD or 1,25(OH)2D is relatively easily available after dissociation from albumin. Thus, the sum of free and albumin-bound forms is called bioavailable 25OHD and bioavailable 1,25(OH)2D. Total 25OHD and 1,25(OH)2D are defined as the sum of free, albumin-bound and DBP-bound 25OHD and 1,25(OH)2D, respectively. This cross-sectional study in 427 pregnant women compared the correlation of the six vitamin D compounds with biomarkers of bone health, lipid metabolism, kidney function, endocrine parameters, and group B water-soluble vitamins. Among the 25OHD metabolites analysed, total 1,25(OH)2D showed clearly the best correlation with calcium, bone-specific alkaline phosphatase, adiponectin, LDL, HDL, urea, thyroxine, and group B water-soluble vitamins. When comparing the three 25OHD metabolites, both free 25OHD and bioavailable 25OHD showed overall good correlations with calcium, bone-specific alkaline phosphatase, adiponectin, LDL, HDL, urea, thyroxine, triiodothyronine, and group B water-soluble vitamins, The correlations of 1,25(OH)2D and 25OHD metabolites went always in opposite directions. Only PTH correlates always inversely with all six vitamin D compounds. In conclusion, free 25(OH)D and bioavailable 25(OH)D are more precise determinants of the vitamin D status than total 25(OH)D in normal pregnancy, whereas total 1,25(OH)2D is superior to free and bioavailable 1,25(OH)2D. Except for PTH, correlations of 25(OH)D and 1,25(OH)2D metabolites with typical clinical chemistry readouts go in opposite directions.

scholarly journals Acute Response of Sclerostin to Whole-body Vibration with Blood Flow Restriction

2021 ◽  
Author(s):  
Kyle S Gapper ◽  
Sally Stevens ◽  
Rona Antoni ◽  
Julie Hunt ◽  
Sarah J Allison
Keyword(s):  
Alkaline Phosphatase ◽  
Blood Flow ◽  
Whole Body Vibration ◽  
Blood Flow Restriction ◽  
Whole Body ◽  
Specific Alkaline Phosphatase ◽  
Body Vibration ◽  
Bone Specific Alkaline Phosphatase ◽  
Flow Restriction ◽  
Acute Response

AbstractBlood flow restriction may augment the skeletal response to whole-body vibration. This study used a randomised, crossover design to investigate the acute response of serum sclerostin and bone turnover biomarkers to whole-body vibration with blood flow restriction. Ten healthy males (mean±standard deviation; age: 27±8 years) completed two experimental conditions separated by 7 days: (i) whole-body vibration (10 1-minute bouts of whole-body vibration with 30 s recovery) or (ii) whole-body vibration with lower-body blood flow restriction (10 cycles of 110 mmHg inflation with 30 s deflation during recovery). Fasting blood samples were obtained immediately before and immediately after exercise, then 1 hour, and 24 hours after exercise. Serum samples were analysed for sclerostin, cross-linked C-terminal telopeptide of type I collagen, and bone-specific alkaline phosphatase. There was a significant time × condition interaction for bone-specific alkaline phosphatase (p=0.003); bone-specific alkaline phosphatase values at 24 hours post-exercise were significantly higher following whole-body vibration compared to combined whole-body vibration and blood flow restriction (p=0.028). No significant time × condition interaction occurred for any other outcome measure (p>0.05). These findings suggest that a single session of whole-body vibration combined with blood flow restriction does not significantly affect serum sclerostin or bone turnover biomarkers.

Sign in / Sign up

Export Citation Format

Share Document